Navigation Links
Hope For Patient With Alzheimer’s Diseas

New research shows combining the drugs memantine and donepezil may improve memory in patients with Alzheimer’s disease. //

Researchers studied more than 300 patients with moderate to severe Alzheimer’s. Participants were already taking the drug donepezil when the study began. Donepezil works by preventing the breakdown of acetylcholine, a chemical messenger in the brain that is important for memory and other thinking skills.For the study, patients received either memantine or a placebo. Memantine targets glutamate, a brain chemical that is associated with nerve cell death when produced in high quantities. The Food and Drug Administration approved memantine in October 2003.

Researchers found patients who took memantine and donepezil experienced significant improvement in cognition, memory, and overall daily functioning compared to those in the placebo group. Researchers say they were pleasantly surprised to see that the two drugs worked well together. Memantine is significant, since it provides an entirely new medication option for the 2.5 million people currently suffering at the advanced stage of Alzheimer’s.

Prior to the FDA’s approval of memantine, only acetylcholinesterase inhibitors, like donepezil, were approved for treating Alzheimer’s patients. Researchers say the study is significant because this is the first time combining two Alzheimer’s drugs has shown positive results.

Researchers conclude saying , “ To find a new medication that can provide substantial benefit to patients at this stage of the disease, either alone or in combination with another Alzheimer’s drug, is certainly good news ... While memantine is not a cure for Alzheimer’s, if it helps to keep a person with Alzheimer’s at home for six months or one year longer, then it is a victoy.”
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. Patients often assume wrongly that they are allergic to penicillin
8. New FDA Approved Drug NATRECOR For Heart Failure Patients
9. Hemochromatosis Patients Blood is Safe
10. Fifth US Patient Receives Artificial Heart
11. Patients Pressure Would Result In Overprescription
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: